Clinical Study
Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
Table 4
Characteristics of different dosimetric approaches concerning acquisition timing and interpolation method.
| Investigator | Therapeutic nuclide | Acquisition timings | Interpolation method |
|
Esser et al. [4], Sandström et al. [5], Larsson et al. [9] |
177Lu | 1, 4, 7 d | MN |
| Hindorf et al. [25] |
90Y | Not fixed, up to 19–48 h, 2–4 acquisitions | Not reported for kidneys |
| Baechler et al. [17] |
90Y, 177Lu, 111In | 0.5, 4 h, 1, 2 d | MN of last three points |
| Cremonesi et al. [3] |
90Y, 177Lu | 1, 4 h, 1, 2, 3 d | MN or BI |
| Garkavij et al. [7] |
177Lu | 1 h, 1, 4, 7 d | TRexp |
|
|